Cargando…

De novo biosynthesis of bioactive isoflavonoids by engineered yeast cell factories

Isoflavonoids comprise a class of plant natural products with great nutraceutical, pharmaceutical and agricultural significance. Their low abundance in nature and structural complexity however hampers access to these phytochemicals through traditional crop-based manufacturing or chemical synthesis....

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Quanli, Liu, Yi, Li, Gang, Savolainen, Otto, Chen, Yun, Nielsen, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526750/
https://www.ncbi.nlm.nih.gov/pubmed/34667183
http://dx.doi.org/10.1038/s41467-021-26361-1
_version_ 1784585928689319936
author Liu, Quanli
Liu, Yi
Li, Gang
Savolainen, Otto
Chen, Yun
Nielsen, Jens
author_facet Liu, Quanli
Liu, Yi
Li, Gang
Savolainen, Otto
Chen, Yun
Nielsen, Jens
author_sort Liu, Quanli
collection PubMed
description Isoflavonoids comprise a class of plant natural products with great nutraceutical, pharmaceutical and agricultural significance. Their low abundance in nature and structural complexity however hampers access to these phytochemicals through traditional crop-based manufacturing or chemical synthesis. Microbial bioproduction therefore represents an attractive alternative. Here, we engineer the metabolism of Saccharomyces cerevisiae to become a platform for efficient production of daidzein, a core chemical scaffold for isoflavonoid biosynthesis, and demonstrate its application towards producing bioactive glucosides from glucose, following the screening-reconstruction-application engineering framework. First, we rebuild daidzein biosynthesis in yeast and its production is then improved by 94-fold through screening biosynthetic enzymes, identifying rate-limiting steps, implementing dynamic control, engineering substrate trafficking and fine-tuning competing metabolic processes. The optimized strain produces up to 85.4 mg L(−1) of daidzein and introducing plant glycosyltransferases in this strain results in production of bioactive puerarin (72.8 mg L(−1)) and daidzin (73.2 mg L(−1)). Our work provides a promising step towards developing synthetic yeast cell factories for de novo biosynthesis of value-added isoflavonoids and the multi-phased framework may be extended to engineer pathways of complex natural products in other microbial hosts.
format Online
Article
Text
id pubmed-8526750
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-85267502021-11-15 De novo biosynthesis of bioactive isoflavonoids by engineered yeast cell factories Liu, Quanli Liu, Yi Li, Gang Savolainen, Otto Chen, Yun Nielsen, Jens Nat Commun Article Isoflavonoids comprise a class of plant natural products with great nutraceutical, pharmaceutical and agricultural significance. Their low abundance in nature and structural complexity however hampers access to these phytochemicals through traditional crop-based manufacturing or chemical synthesis. Microbial bioproduction therefore represents an attractive alternative. Here, we engineer the metabolism of Saccharomyces cerevisiae to become a platform for efficient production of daidzein, a core chemical scaffold for isoflavonoid biosynthesis, and demonstrate its application towards producing bioactive glucosides from glucose, following the screening-reconstruction-application engineering framework. First, we rebuild daidzein biosynthesis in yeast and its production is then improved by 94-fold through screening biosynthetic enzymes, identifying rate-limiting steps, implementing dynamic control, engineering substrate trafficking and fine-tuning competing metabolic processes. The optimized strain produces up to 85.4 mg L(−1) of daidzein and introducing plant glycosyltransferases in this strain results in production of bioactive puerarin (72.8 mg L(−1)) and daidzin (73.2 mg L(−1)). Our work provides a promising step towards developing synthetic yeast cell factories for de novo biosynthesis of value-added isoflavonoids and the multi-phased framework may be extended to engineer pathways of complex natural products in other microbial hosts. Nature Publishing Group UK 2021-10-19 /pmc/articles/PMC8526750/ /pubmed/34667183 http://dx.doi.org/10.1038/s41467-021-26361-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Liu, Quanli
Liu, Yi
Li, Gang
Savolainen, Otto
Chen, Yun
Nielsen, Jens
De novo biosynthesis of bioactive isoflavonoids by engineered yeast cell factories
title De novo biosynthesis of bioactive isoflavonoids by engineered yeast cell factories
title_full De novo biosynthesis of bioactive isoflavonoids by engineered yeast cell factories
title_fullStr De novo biosynthesis of bioactive isoflavonoids by engineered yeast cell factories
title_full_unstemmed De novo biosynthesis of bioactive isoflavonoids by engineered yeast cell factories
title_short De novo biosynthesis of bioactive isoflavonoids by engineered yeast cell factories
title_sort de novo biosynthesis of bioactive isoflavonoids by engineered yeast cell factories
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526750/
https://www.ncbi.nlm.nih.gov/pubmed/34667183
http://dx.doi.org/10.1038/s41467-021-26361-1
work_keys_str_mv AT liuquanli denovobiosynthesisofbioactiveisoflavonoidsbyengineeredyeastcellfactories
AT liuyi denovobiosynthesisofbioactiveisoflavonoidsbyengineeredyeastcellfactories
AT ligang denovobiosynthesisofbioactiveisoflavonoidsbyengineeredyeastcellfactories
AT savolainenotto denovobiosynthesisofbioactiveisoflavonoidsbyengineeredyeastcellfactories
AT chenyun denovobiosynthesisofbioactiveisoflavonoidsbyengineeredyeastcellfactories
AT nielsenjens denovobiosynthesisofbioactiveisoflavonoidsbyengineeredyeastcellfactories